Clinical analysis of prediction for recurrence of gynecological tumors through serum HE4, CA72-4 and VEGF levels / 中国医学装备

ABSTRACT

Objective:To explore the predictive value of human serum epididymis protein 4 (HE4), carbohydrate antigen 72-4 (CA72-4) and vascular endothelial growth factor (VEGF) for the recurrent risk of gynecological tumor. Methods: A total of 142 patients with gynecologic malignant tumors were divided into the observation group, and all of them were followed up, and their recurrence rate within 2 years after operation was calculated. At the same time, 50 healthy women were divided into control group. The peripheral venous blood of all subjects were collected to test serum HE4 and VEGF levels by using enzyme-linked immunosorbent assay (ELISA). The serum CA72-4 was detected by using Roche electrochemiluminescence immunoassay. Three indicators of two groups were compared. Results: Before treatment, the serum HE4, CA72-4 and VEGF levels of the observation group were significantly higher than those of the control group (t=58.971,t=26.795,t=42.021;P<0.01). And the positive rate of HE4, CA72-4 and VEGF of the gynecological tumor group were significantly higher than those of the control group (x2=50.061, x2=37.596,x2=43.765,P<0.01). Within post-operative 2 years, there were 84 cases were recurrence in observation group. And the HE4, CA72-4 and VEGF of recurrent patients were significantly higher than that of non-recurrent patients (t=53.075,t=22.211,t=55.948,P<0.01).The sensitivity and negative predictive value of the combined detection of 3 indicators were significantly larger than that of single detection of CA72-4 (x2=8.537,x2=5.345, P<0.05).Conclusion: Patients with gynecological malignant tumor have high expression of serum HE4, CA72-4 and VEGF and the combined detection of 3 indexes possessed more sensitive, and it has greater predictive value for the recurrent risk of gynecologic malignant tumor.